JD.Com Inc vs McKesson Corporation — how do they compare? JD.Com Inc trades at $31.45 (market cap $44.04B), while McKesson Corporation trades at $899.7 (market cap $105.14B). The key difference: McKesson Corporation is far larger — about 2.4× JD.Com Inc's market cap, and JD.Com Inc pays the higher dividend (3.13%). Which is the better fit depends on your goals.
| JD | MCK | |
|---|---|---|
Market Cap | $44.04B | $105.14B |
Sector | Consumer Cyclical | Health |
52-Week High | $36.17 | $995.69 |
52-Week Low | $25.19 | $659.01 |
Enterprise Value | $30.10B | $111.67B |
Dividend Yield | 3.13% | 0.42% |
Signals from Pluang's Aura AI — not financial advice
JD.com trades at $33.47, up 1.52% today, with a bullish technical setup as price consolidates near recent highs. The company reported strong Q1 2026 earnings, beating estimates with EPS of $0.74 versus $0.57 expected, while revenue reached $1.31 trillion in 2025. Analyst consensus remains strongly positive with a $38.00 price target, though regulatory scrutiny from EU authorities over the Ceconomy acquisition presents a near-term headwind.
JD offers attractive valuation with a P/S of 0.24 and consistent earnings beats, but faces margin pressure and regulatory risks. Upside potential exists if Q2 2026 results meet high expectations, but investors must weigh competitive pressures in e-commerce and macroeconomic challenges affecting Chinese equities.
No Aura AI signal available yet.
Trailing returns across standard periods
Latest headlines on both assets
JD.com is China's second-largest e-commerce company after Alibaba in terms of gross merchandise volume, offering a wide selection of authentic products at competitive prices, with speedy and reliable delivery. The company has built its own nationwide fulfilment infrastructure and last-mile delivery network, staffed by its own employees, which supports both its online direct sales, its online marketplace and omnichannel businesses.
Read more on JD →McKesson is a leading wholesaler of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and Cardinal Health, the three account for well over 90% of the U.S. pharmaceutical wholesale industry. McKesson is currently divesting from its pharmaceutical wholesale and distribution in Europe and Canada in order to redeploy capital to strategic growth areas in the U.S. (oncology network and ecosystem, and biopharma services). Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.
Read more on MCK →